Obsessive-Compulsive Disorder (OCD) Clinical Trials

Find Obsessive-Compulsive Disorder (OCD) Clinical Trials Near You

Assessment of Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment Refractory Obsessive Compulsive Disorder (OCD)

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study evaluates the safety, feasibility, and preliminary efficacy of focused ultrasound (FUS) neuromodulation delivered using the Next Generation Dome Helmet (NGDH) in participants with treatment-refractory obsessive-compulsive disorder (OCD). Participants will undergo two study sessions, four weeks apart, involving active FUS neuromodulation targeting nodes of the cortico-striato-thalamo-cortical (CTSC) circuit. Outcomes include adverse events, changes in OCD symptom severity, and quality of life.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Must be deemed to have the capacity to provide informed consent.

• Age 18 to 85 years.

• Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria.

• Yale-Brown Obsessive Compulsive Scale total score greater than 22.

• If taking psychiatric medications, must be on a stable regimen for at least 30 days before enrollment. Psychiatric medications will be continued throughout the study.

• Previous trial of at least two first-line antidepressant agents at an adequate dose and duration, as assessed by two psychiatrists.

• Previous trial of cognitive behavioural therapy or psychotherapy for OCD for at least 6 weeks.

Locations
Other Locations
Canada
Sunnybrook Health Sciences Centre
RECRUITING
Toronto
Contact Information
Primary
Nir Lipsman, MD, PHD, FRCSC, FAANS
Nir.Lipsman@sunnybrook.ca
(416)-480-6954
Backup
Anusha Baskaran, PhD
anusha.baskaran@sunnybrook.ca
416-480-6100
Time Frame
Start Date: 2025-09-23
Estimated Completion Date: 2027-09
Participants
Target number of participants: 20
Treatments
Experimental: Focused Ultrasound Neuromodulation
Focused Ultrasound Neuromodulation: Participants will receive two sessions of Magnetic Resonance-guided focused ultrasound neuromodulation targeting regions within the cortical-striatal-thalamic circuit (CSTC) implicated in treatment-resistant depression. Treatments will be spaced four weeks apart. All participants will receive the same intervention and will be followed for 4 weeks post-treatment to evaluate clinical outcomes, adverse events, and depression symptoms.
Related Therapeutic Areas
Sponsors
Leads: Sunnybrook Health Sciences Centre

This content was sourced from clinicaltrials.gov